Editas Medicine — Third Quarter 2026 Earnings Summary

Editas Medicine received Human Research Ethics Committee approval to initiate the Phase 1/2 Strive study of its gene editing candidate EDIT-401 for hyperlipidemia in Australia, with patient dosing expected to begin in 2026. New preclinical data presented at the American Heart Association Scientific Sessions demonstrated that EDIT-401 maintained LDL-C reductions of at least 90 percent over 10 months in non-human primates. The company also reported that a second IND/CTA for its CD70 HD Allo CAR T program with Bristol Myers Squibb was accepted, triggering a milestone payment. Financially, Editas reported a net loss of $23.4 million for the third quarter of 2026 and holds $190.2 million in cash, cash equivalents, and marketable securities, which supports operations through the second half of 2028.